CN-121714563-B - Application of scopoletin in preparation of anti-white spot syndrome medicine

Abstract

The invention belongs to the technical field of fishing medicines, relates to specific therapeutic activity of scopoletin, and in particular relates to application of scopoletin in preparation of medicines for resisting white spot syndrome. Experiments prove that scopoletin lactone can endow aquatic animals such as prawns with a certain capacity of resisting white spot syndrome virus by inducing up-regulation of key members Ago2 and Dicer2 genes in an RNAi antiviral mechanism of the prawns.

Inventors

• WANG XIANWEI
• WANG WEIGUANG
• ZHAO YONGZHEN
• KANG DONGWEI

Assignees

• 山东大学

Dates

Publication Date

20260512

Application Date

20260225

Claims (10)

1. 1. Application of scopoletin in preparing medicine for treating leukoplakia syndrome is provided.
2. 2. The use according to claim 1, wherein the medicament has at least one of the following effects: (a) Inducing the expression of Ago2 gene and Dicer2 gene which are core components of RNAi mechanism of aquatic animals; (b) Inhibiting mRNA transcription of the white spot syndrome virus structural protein VP28 gene; (c) Inhibiting replication of intact virions of white spot syndrome virus; (d) Inhibit death of prawn caused by white spot syndrome virus.
3. 3. The use according to claim 1, wherein the active ingredient of the medicament is scopoletin or a pharmaceutically acceptable salt thereof.
4. 4. The use according to claim 1, wherein the medicament is as a feed additive for aquatic animals.
5. 5. The use according to claim 1, wherein the medicament is administered by feed addition or water administration.
6. 6. The use according to claim 1, wherein the drug is administered at a concentration of 50 μg/L.
7. 7. The use according to claim 1, wherein the medicament is a composition.
8. 8. The use according to claim 7, wherein the composition comprises a pharmaceutical excipient.
9. 9. The use according to claim 1, wherein the subject to which the medicament is administered is an aquatic animal.
10. 10. The use according to claim 9, wherein the aquatic animal is a shrimp.

Description

Application of scopoletin in preparation of anti-white spot syndrome medicine Technical Field The invention belongs to the technical field of fishing medicines, relates to specific therapeutic activity of scopoletin, and in particular relates to application of scopoletin in preparation of medicines for resisting white spot syndrome. Background The disclosure of this background section is only intended to increase the understanding of the general background of the invention and is not necessarily to be construed as an admission or any form of suggestion that this information forms the prior art already known to those of ordinary skill in the art. White spot syndrome (White Spot Syndrome, WSS) is one of the most dangerous diseases in the shrimp farming industry. The pathogen of the disease is White Spot Syndrome Virus (WSSV), a double-stranded DNA virus with a capsule, which can cause rapid death of prawns within 3-10 days. Based on the existing research, WSSV prevention lacks effective means. The prawn relies on its innate immune system to construct an effective antiviral defense network, which provides a molecular basis for developing novel prevention and control strategies. The antiviral immune core mechanism of the prawn is RNAi (RNA interference) reaction, long double-stranded RNA of the virus is identified and cut through Dicer-2 protein to generate small interfering RNA (siRNA) with virus specificity, and then the siRNA is loaded into an RNA induction silencing complex formed by Ago2 protein, and the viral messenger RNA is cut through base complementary pairing in a targeted way, so that the expression and replication of viral genes are inhibited at the posttranscriptional level. Previous experimental data indicate that up-regulating the expression of the prawn Dicer-2 or Ago2 genes significantly enhances antiviral ability. Therefore, if a new antiviral drug can be developed, the expression quantity of key members of an RNAi mechanism can be simultaneously improved, so that the antiviral capability of the prawns is improved, WSSV infection can be effectively inhibited, white spot syndrome is treated, and the method has important significance for protecting the healthy development of the prawn breeding industry. Disclosure of Invention Scopoletin is also called scopoletin, and the main medical application reported for scopoletin at present comprises anti-inflammatory, neuroprotection, anti-diabetes and the like, and no record is made on the use of scopoletin in fishing medicines. Experiments prove that scopoletin can induce the expression level of core members of an antiviral RNAi mechanism in a prawn body, inhibit the replication of WSSV gene mRNA and complete virus particles, and relieve the injury of white spot syndrome to the body. This suggests that scopoletin can confer a certain antiviral ability to prawns by inducing the expression of antiviral genes. The application system of the invention for the antiviral drugs of aquatic animals such as scopoletin is disclosed for the first time, and is different from the known application of scopoletin. Based on the research results, the invention provides application of scopoletin in preparation of anti-white spot syndrome medicines. Specifically, the technical scheme provided by the invention is as follows: in a first aspect, the use of scopoletin for the manufacture of a medicament for the treatment of leukoplakia syndrome. The scopoletin lactone has the CAS number of 92-61-5 and the chemical structural formula shown as follows: 。 in some embodiments, the medicament has at least one of the following effects: (a) Inducing the expression of Ago2 gene and Dicer2 gene which are core components of RNAi mechanism of aquatic animals; (b) Inhibiting mRNA transcription of the white spot syndrome virus structural protein VP28 gene; (c) Inhibiting replication of intact virions of white spot syndrome virus; (d) Inhibit death of prawn caused by white spot syndrome virus. In some embodiments, the active ingredient of the medicament is scopoletin or a pharmaceutically acceptable salt, solvate, hydrate thereof. The pharmaceutically acceptable salt according to the present invention means a salt which is considered pharmaceutically safe, effective and suitable for use in pharmaceutical formulations, and may be a salt with an inorganic or organic acid, or a salt with an inorganic or organic base. Wherein the inorganic acid can be sulfuric acid, hydrochloric acid, phosphoric acid, nitric acid, etc., the organic acid can be acetic acid, oxalic acid, citric acid, fumaric acid, p-toluenesulfonic acid, etc., the inorganic base can be sodium hydroxide, potassium hydroxide, ammonia water, etc., and the organic base can be methylamine, ethylamine, ethanolamine, etc. The solvate refers to a crystal structure formed by scopoletin and crystallization of an organic solvent. The hydrate disclosed by the invention refers to a crystal structure formed by scopoletin and water crystalliza